Previous 10 | Next 10 |
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q1 2021 Earnings Call May 06, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Athersys (ATHX) Q1 2021 Earnings Call Transcript
Athersys (ATHX): Q1 GAAP EPS of -$0.13 misses by $0.02.Revenue of $0M misses by $1.27M.At March 31, 2021, the company had $64.2M in cash and cash equivalents, compared to $51.5M at December 31, 2020.Press Release For further details see: Athersys EPS misses by $0.02, misses on revenue ...
Management to host conference call at 4:30 pm EDT today Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2021 and provided a corporate update. “Since our recent call, we remain on track with respect to ou...
Ivor Macleod, Chief Financial Officer of Athersys Inc. (NASDAQ: ATHX), is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 12:30 pm EDT. Following a brief corporate update, Mr. Macleod will engage in a Q & A fires...
Athersys, Inc. (NASDAQ: ATHX) announced today that Mr. Ivor Macleod, Chief Financial Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Wednesday, April 14, 2021 at 1:30 pm EDT. The company will also eng...
Athersys ([[ATHX]] +6.1%) has announced that its partner HEALIOS K.K., a clinical stage biotech in Japan, has completed enrollment in the ONE-BRIDGE study in Japan.The trial consisting of two cohorts is designed to demonstrate the safety and efficacy of MultiStem treatment for patients w...
Off-the-shelf stem cell therapy has potential to enhance recovery for ARDS patients Athersys, Inc. (Nasdaq: ATHX) announced today that its partner HEALIOS K.K. (Healios) has completed enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem ® (invimestro...
Athersys, Inc. (ATHX) Q4 Full Year 2020 Earnings Conference Call March 25, 2021 4:30 PM ET Company Participants Karen Hunady – Director-Corporate Communications and Investor Relations B.J. Lehmann – Interim Chief Executive Officer Ivor Macleod – Chief Financial Officer Co...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q4 2020 Earnings Call Mar 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Athersys (ATHX) Q4 2020 Earnings Call Transcript
Athersys (ATHX): FY GAAP EPS of -$0.11 beats by $0.32.Revenue of $1.27M (+337.9% Y/Y) beats by $0.99M.Press Release For further details see: Athersys EPS beats by $0.32, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...